Global H1N1 Vaccines Industry - KXNet.com - Bismarck/Minot/Williston/Dickinson-KXNEWS,ND

Global H1N1 Vaccines Industry

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, May 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Global H1N1 Vaccines Industry

http://www.reportbuyer.com/pharma_healthcare/therapeutic/global_h1n1_vaccines_industry.html

This report analyzes the Global market for H1N1 Vaccines in US$ Million.

The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018.

The report profiles 29 companies including many key and niche players such as Abbott Laboratories, Baxter International, Inc., CPL Biologicals Pvt. Ltd., CSL Limited, bioCSL, GlaxoSmithKline Plc, MedImmune, LLC, Novartis AG, Sanofi Pasteur, SA, Sinovac Biotech Ltd., and Zydus Cadila.

Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW II-1
A Prelude II-1
Current and Future Analysis II-2
Challenges Facing Healthcare Industry in Tackling Pandemics II-2
Cumbersome Production Process of Pandemic Vaccines II-2
Inefficiencies in Vaccine Distribution: A Cause of Concern II-2
Competitive Scenario II-3
H1N1 Influenza Vaccines and Manufacturers II-3

2. GROWTH DRIVERS & INHIBITORS II-4
Key Growth Drivers II-4
Emerging Economies Present Potent Markets for H1N1 Vaccines II-4
Consumer Awareness About Influenza Vaccines on the Rise II-4
Threat of Antigenic Shift of H1N1 Virus Lingers II-5
Influenza A(H1N1) pdm09 Virus Continues to Influence Global
Influenza Activity II-5
Government Purchases Continue to Propel Sales II-5
Table 1: Mortality Rates of Major Influenza Pandemics Over
the Last 100 Years (includes corresponding Graph/Chart) II-6
Key Growth Inhibitors II-7
High Competition Lowers Profit Margins II-7
Shorter Lifecycle Of Pandemic Influenza II-7
Ongoing Financial Crisis Affects Drug Prices and
Manufacturing Cycles II-7
Large-Scale Investments Pose Entry Barriers for Smaller Players II-8

3. AN INSIGHT INTO GLOBAL VACCINES MARKET II-9
Vaccines Market to Witness Robust Increase in Sales Driven by
Robust Demand II-9
Pneumococcal and Pediatric Multivalent Vaccines Dominate Sales II-10
Table 2: Global Vaccines Market by Category (2012):
Percentage Breakdown of Value Sales for Pneumococcal,
Pediatric Multivalent, HPV, Influenza, Hepatitis, Rotavirus,
Adult Booster, Meningococcal and Shingles (includes
corresponding Graph/Chart) II-10
Competitive Scenario II-11
Table 3: Global Vaccines Market by Leading Manufacturer
(2012): Percentage Market Share Breakdown of Value Sales for
Sanofi Pasteur, GlaxoSmithKline, Merck & Co, Pfizer,
Novartis Vaccines & Diagnostics, Astra Zeneca and Others
(includes corresponding Graph/Chart) II-11
H1N1 Influenza Diagnostic Tests II-11
Table 4: Global Laboratory Rapid Testing by Leading Players
(2012): Percentage Market Share Breakdown of Value Sales for
Alere, Quidel, Meridian Bioscience, Beckman Coulter/Danaher,
OraSure and Others (includes corresponding Graph/Chart) II-12
Major Trends II-13
Antigenic Shift of Virus Unlocks Possibilities for New
Seasonal Influenza Vaccines II-13
Quadrivalent Vaccines - A Whole New Generation of Seasonal
Influenza Vaccines II-13
Innovations in Vaccine Technology to Drive the Effort for a
Universal Influenza Vaccine II-14

4. H1N1 PANDEMIC - A HISTORICAL PERSPECTIVE II-15
Influenza A (H1N1) 2009: The Global Pandemic II-15
Table 5: Global Death Toll from 2009 A H1N1 (2009-2012)
(includes corresponding Graph/Chart) II-16

5. ECONOMIC IMPACT OF H1N1 PANDEMIC IN RETROSPECT II-17
Pork & Pork Products II-17
Airlines, Tourism & Hospitality II-17
Hand Sanitizers II-18
Table 6: US Market Revenues for Hand-Sanitizers for the Years
2008 through 2012 in US$ Millions (includes corresponding
Graph/Chart) II-19
Healthcare & Pharmaceuticals II-19

6. H1N1 INFLUENZA - AN OVERVIEW II-20
Influenza Virus: A Quick Primer II-20
Symptoms and Characteristics II-20
Types of Influenza II-20
Influenza A Virus II-20
Influenza A (H1N1) Virus II-20
Different Names, in Different Countries II-20
Symptoms and Risk Factors II-21
The Pandemic Life-Cycle II-21
Seasonal Influenza vis-à-vis H1N1 Flu II-22
How H1N1 Is Diagnosed? II-22
Prevention and Vaccination Against H1N1 II-22
Prevention II-22
Vaccination II-22
Vaccine Virus Selection for the 2012-2013 Influenza Season II-23
WHO Recommended Virus Strains for Seasonal Influenza
Vaccines for Northern Hemisphere for 2013-2014 II-23
WHO Recommended Virus Strains for Seasonal Influenza
Vaccines for Southern Hemisphere for 2013 II-24
How H1N1 Vaccine is Prepared? II-24
Egg-Based Production Process II-24
Cell Culture-Based Technology II-25
Recombinant Technology II-25
Side Effects of H1N1 Vaccine II-26
Primary Targets for Vaccination II-26
Adverse Group for Vaccination II-26
Treatment for Swine-Flu Infected Individuals II-26
Anti-Virals for Pandemic (H1N1) 2009 Infection II-27
Recommended Dosage of Anti-Viral II-27
Peramivir - An Investigational Antiviral for H1N1 II-27

7. REGULATORY APPROVALS II-28
GSK Obtains Marketing Authorization for Quadrivalent Influenza
Vaccine in the UK and Germany II-28
Sanofi Pasteur's Review Application for Quadrivalent Influenza
Vaccine Accepted by EU II-28
MedImmune Announces FDA Clearance of First Quadrivalent Flu
Vaccine II-29
Novartis Announces FDA Approval for Cell-Culture Derived Vaccine II-30
GlaxoSmithKline Obtains FDA Approval for FLUARIX® QUADRIVALENT II-30
Tianyuan Receives GMP Certification for Influenza and H1N1
Vaccine II-31
Kitasato Daiichi Sankyo Vaccine and Daiichi Sankyo Group
Obtain Approval from Japanese Government for H1N1 Vaccine
Production II-31
Baxter Secures rMRP Approval from Austrian Agency for Health
and Food Safety II-32
AstraZeneca Announces European Commission's Approval of FLUENZ
Vaccine II-32

8. REGULATORY APPROVALS IN THE RECENT PAST II-33
Serum Institute of India Secures Approval from DCGI for Usage
of HIN1 Injectable Vaccine II-33
Quest Diagnostics Obtains Approval for Simplexa Influenza A
H1N1 Test from FDA II-33
Zydus Cadila Obtains Approval from DCGI II-33
Intelligent Medical Devices Receives FDA Approval for Usage of
H1N1 Influenza Virus Assay II-33
CSL Biotherapies Receives TGA Approval for Panvax® H1N1 II-34
WHO Prequalifies Arepanrix™ H1N1 Vaccine of GlaxoSmithKline II-34
CSL Obtains Approval for Extended Use of 2009 HINI Influenza
vaccine in Infants II-34
Novartis Receives Approval for Celtura® II-34
Baxter Obtains Approval for Vero Cell-Based CELVAPAN H1N1
Vaccine in Europe II-34
CHMP Recommends Approval of Novartis' Focetria® in Europe II-35
Sanofi Pasteur Obtains License from the US FDA for Influenza A
(H1N1) 2009 Monovalent Vaccine II-35
Sanofi Pasteur Receives Approval for New Vaccine Production
Facility II-35
US FDA Approves Supplemental BLA of GSK, for Unadjuvanted
Influenza A (H1N1) Pandemic Vaccine II-35
Health Canada Approves H1N1 Virus Vaccine II-36
Sanofi Pasteur Gains Approval of Afssaps for A (H1N1) 2009
Vaccine in France II-36
Novartis Obtains Prequalification Status from the WHO for
Supply of Influenza A (H1N1) 2009 Vaccines in Developing
World II-36
Novartis Obtains Swissmedic Approval for Celtura® II-36
CSL Biotherapies Receives US FDA Licensure for its Thimerosal-
free Pandemic Influenza A (H1N1) 2009 Monovalent Vaccine II-37
MedImmune Receives US FDA Approval for Nasal Spray H1N1 Vaccine II-37
Sinovac Obtains Revised Approval for PANFLU.1 (H1N1) from
State Food and Drug Administration II-37
Sinovac Gains Certificate of Approval for Supply of PANFLU.1
in Mexico II-38
Jiangsu Yanshen Gains Manufacturing License from SFDA, for
H1N1 Flu Vaccine II-38

9. PRODUCT LAUNCHES II-39
FGBU Federal Center Develops H1N1 Swine Flu Inactivated Vaccine II-39
Biolab Launches New Diagnostic Test for Swine Flu II-39
VABIOTECH Develops Vaccines for A/H1N1 and A/H5N1 Viruses II-39
Focus Diagnostics and 3M Unveil Simplexa™ Test on 3M™
Integrated Cycler II-40
Bharat Biotech Introduces HNVAC H1N1 Swine Flu Vaccine II-40
Serum Institute Unveils Nasovac Nasal Vaccine II-41
Zydus Cadila Rolls Out Vaxiflu-S H1N1 Vaccine II-41
The Scientific Research Institute Introduces New A/H1N1 Flu
Vaccine II-41

10. RECENT INDUSTRY ACTIVITY II-42
bioCSL Restarts Manufacture of Influenza Vaccine II-42
bioCSL Obtains Government Contracts for Vaccine Distribution II-42
InGen Biosciences Inks Exclusive Dual Partnership Agreements II-42
Vical and U.S. Naval Medical Research Center Extend Collaboration II-43
Seegene and H1N1 Cross-Agencies Task Force Sign Research
Agreement II-43

11. INDUSTRY ACTIVITIES IN THE RECENT PAST II-44
Vical and GenomIdea Ink Evaluation and Supply Agreement II-44
Sinovac Biotech Signs Exclusive Distribution and Supply
Licensing Agreement with Parenteral Biotech II-44
Biological E Obtains License from VaxInnate for H1N1 Pandemic
Swine Flu Vaccine II-44
Fraunhofer USA Initiates Human Trial of H1N1 Influenza Vaccine II-44
Novavax Announces Positive Results of A/H1N1 Pandemic
Influenza Vaccine II-45
Sinovac Biotech Clinches Fifth Consecutive Supply Order from
MIIT for Panflu.1 H1N1 Vaccine II-45
Zydus Cadila Completes Phase I Clinical Trial With its H1N1
Vaccine II-45
Cadila Pharmaceuticals and Novavax Launch CPL Biologicals Pvt.
Ltd. II-46
Novartis Delivers 7.5 Million Doses of Influenza A (H1N1)
Vaccine to HHS II-46
Novartis Opens New Production Facility for Cell Culture-Based
Influenza Vaccines Production in the United States II-46
Novartis to Takeover Majority Interest in Chinese H1N1 Vaccine
Maker II-47
PhageVax Launches DNA Vaccine Platform II-47
NIH to Initiate 2009 H1N1 Influenza Vaccine Trial in Persons
with Asthma II-47
Inovio Teams Up with Canadian Health Agency Pennsylvanian
University on Swine Flu Vaccine II-47
Simcere to Acquire Majority Interest in ChinaVax II-48
Sanofi Pasteur Clinches Additional Order from HHS Department
of the US II-48
Sanofi Pasteur Bags Order from French Health Ministry, for
Influenza A (H1N1) Vaccine II-48
Sanofi Pasteur Inks Deal with Butantan Institute for Supply of
Influenza A (H1N1) Virus Vaccine II-48
McKesson Extends Partnership Deal with CDC II-48
BD Receives Order from the Department of HHS II-49
GSK Receives Order from the Department of HHS II-49
MedImmune Recalls 4.7 Million Courses of Nasal H1N1 Flu Vaccine II-49
Novavax and Xcellerex Enter into a Partnership II-49

12. FOCUS ON SELECT GLOBAL PLAYERS II-50
Abbott Laboratories (US) II-50
Baxter International, Inc. (US) II-50
CPL Biologicals Pvt. Ltd (India) II-51
CSL Limited (Australia) II-51
bioCSL (Australia) II-52
GlaxoSmithKline Plc. (UK) II-52
MedImmune, LLC. (USA) II-53
Novartis AG (Switzerland) II-53
Sanofi Pasteur, SA (France) II-54
Sinovac Biotech Ltd. (China) II-55
Zydus Cadila (India) II-55

13. GLOBAL MARKET PERSPECTIVE II-56
Table 7: World Recent Past, Current & Future Analysis for H1N1
Vaccines by Geographic Region - North America, Europe,
Asia-Pacific, and Rest of World Markets Independently Analyzed
by Annual Sales Figures in US$ Million for the Years 2009
through 2018 (includes corresponding Graph/Chart) II-56

Table 8: World 10-year Analysis for H1N1 Vaccines by
Geographic Region - Percentage Breakdown of Dollar Sales for
North America, Europe, Asia-Pacific, and Rest of World Markets
for the Years 2009, 2013 and 2018 (includes corresponding
Graph/Chart) II-57

III. MARKET

1. NORTH AMERICA III-1
A.Market Analysis III-1
Medicare and Medicaid Services for Influenza in the US III-1
Table 9: CDC Price List for Pediatric Influenza Vaccines in
Basic Package: 2013-2014 III-1
Table 10: CDC Price List for Adult Influenza Vaccines in
Basic Package: 2013-2014 III-2
Rapid Spread of the H1N1 Pandemic Pegged to Delay in Vaccine
Administration III-2
Swine Flu Pandemic Undermines US Pork Exports Considerably III-2
Restrictions Imposed on Various Pork Products in Russia and
China during Pandemic A H1N1Outbreak III-3
Table 11: US Pork Exports by Destination Country (2008 &
2013E): Percentage Breakdown of Export Value for Japan,
Mexico, China & Hong Kong, Canada, Russia, and Others
(includes corresponding Graph/Chart) III-3
A Historical Perspective on the H1N1 Pandemic in North America III-3
First Case of H1N1 Infection Reported in Mexico III-3
Swine Flu Spreads to the United States III-4
Canadian Government Launches H1N1 Mass Vaccination Campaign III-4
Major H1N1 Vaccines Available in North American Marketplace III-4
US FDA-Approved Influenza Vaccines with 2009 H1N1 Virus
Strain Indicated for 2013-2014 Flu Season III-4
US FDA-Approved Quadrivalent Vaccines Incorporating H1N1
Strain for Influenza Type A and B (2013) III-5
Preparations Authorized by Health Canada for Influenza,
including H1N1, in Canada (2013) III-5
Product Approvals & Launches III-5
Strategic Corporate Developments III-7
Select Key Players III-8
B.Market Analytics III-10
Table 12: North American Recent Past, Current & Future
Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures
in US$ Million for the Years 2009 through 2018 (includes
corresponding Graph/Chart) III-10

2. EUROPE III-11
A.Market Analysis III-11
Insights into European Influenza Vaccination Scenario III-11
Cell-based Vaccine Production Remains Nascent III-11
Major Influenza Vaccines Available in European Union Member
Countries III-11
Major H1N1 Flu Vaccines Available in Select East European
Markets III-12
ECDC Proposes New Influenza Vaccination Strategy III-12
Immunization of High-Risk Demographics III-12
Protecting Children, Adolescents, and Young Adults III-12
Stemming the Spread of Infection in Public Centers III-12
EMA approval for Quadrivalent LAIVs Pending III-13
Anticipated Enhancements in Influenza Vaccine Products III-13
Historical Perspective on the H1N1 Pandemic in Europe III-13
Product Approvals & Launches III-14
Strategic Corporate Developments III-16
Select Key Players III-17
B.Market Analytics III-20
Table 13: European Recent Past, Current & Future Analysis
for H1N1 Vaccines Analyzed by Annual Sales Figures in US$
Million for the Years 2009 through 2018 (includes
corresponding Graph/Chart) III-20

3. ASIA-PACIFIC III-21
A.Market Analysis III-21
Leading Influenza H1N1 Vaccine Brands Available in Select
Asia-Pacific Markets III-21
Historical Perspective on the Outbreak of H1N1 Pandemic in
2009 in Select Regions III-21
Japan III-21
South Korea III-21
Taiwan III-21
Malaysia III-22
Philippines III-22
New Zealand III-22
India III-22
China III-23
Hong Kong III-23
Singapore III-23
Australia III-24
Product Approvals & Launches III-24
Strategic Corporate Developments III-25
Select Players III-26
B.Market Analytics III-29
Table 14: Asia-Pacific Recent Past, Current & Future
Analysis for H1N1 Vaccines by Geographic Region Analyzed by
Annual Sales Figures in US$ Million for the Years 2009
through 2018 (includes corresponding Graph/Chart) III-29

4. REST OF THE WORLD III-30
A.Market Analysis III-30
Product Approvals & Launches III-30
B.Market Analytics III-31
Table 15: Rest of the World Recent Past, Current & Future
Analysis for H1N1 Vaccines by Geographic Region Analyzed by
Annual Sales Figures in US$ Million for the Years 2009
through 2018 (includes corresponding Graph/Chart) III-31

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 29 (including Divisions/Subsidiaries - 33)

The United States (11)
Canada (1)
Japan (2)
Europe (6)
- France (1)
- The United Kingdom (2)
- Rest of Europe (3)
Asia-Pacific (Excluding Japan) (13)

Read the full report:
Global H1N1 Vaccines Industry

http://www.reportbuyer.com/pharma_healthcare/therapeutic/global_h1n1_vaccines_industry.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
General information or questions:
kxinfo@kxnet.com

News:
Bismarck:
Phone: 701-223-9197
News Fax: 701-223-1985

News:
Minot:
Phone: 701-852-2104
News Fax: 701-838-1050
All content © Copyright 2000 - 2014 WorldNow and KXNET. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.